Mutations in the cystathionine beta-synthase (CBS) gene are the cause of classical homocystinuria, the most common inborn error in sulfur metabolism. The c.797 G>A (p.R266K) mutation in CBS was originally described in several Norwegian pyridoxine responsive CBS deficient patients, and heterologous gene expression studies have shown that the protein has near wild-type levels of enzyme activity. Here, we characterize a transgenic mouse lacking endogenous Cbs and expressing p.R266K human CBS protein from a zinc inducible metallothionein promoter (Tg-R266K Cbs -/-).
INTRODUCTION
Cystathionine -synthase (CBS) deficiency (MIM# 236200) is the most common inborn error of sulfur metabolism and is the cause of classical homocystinuria (Mudd, 2011) . CBS catalyzes the condensation of homocysteine with serine to form cystathionine, which is the first step in the de novo production of cysteine. CBS deficient patients are characterized by extreme elevations in plasma total homocysteine (tHcy). In healthy adults, tHcy concentration in plasma ranges from 5 to 15 M, but untreated patients with CBS deficiency often have tHcy in excess of 200 M. CBS-deficient patients suffer at an early age from various pathologies including thrombosis, osteoporosis, mental retardation, and dislocated lenses. The major cause of mortality and morbidity in these patients is thrombosis. Current treatment strategies involve dietary restriction and vitamin therapy, but these are only partially effective and do not work in all patients. Recent preclinical studies suggest that CBS enzyme replacement may be a possible future treatment (Bublil et al., 2016) .
CBS encodes a 63 kDa protein that is 551 amino acids in length and is normally functional as a homotetramer (Kraus, Packman, Fowler, & Rosenberg, 1978) . Human CBS protein contains three functional domains: An N-terminal domain that binds heme (aa 1-75), a core domain (aa 76-398) that contains the catalytic site which binds pyridoxal 5'-phosphate (PLP) and shares similarity with other PLP-utilizing enzymes, and a C-terminal regulatory domain that is responsible for allosteric regulation by S-adenosylmethionine (aa 399-551) (Jhee & Kruger, 2005) . In patients with CBS deficiency, at least 924 mutant alleles have been characterized with 85% of these being missense mutations (see http://cbs.lf1.cuni.cz/index.php). Many missense mutant CBS enzymes have been expressed in cell-based heterologous expression systems such as E. coli and S. cerevisiae (Kozich & Kraus, 1992; Kraus et al., 1999; Kruger, 1994) . Although most expressed mutant proteins have greatly reduced enzyme activities, several do not. This suggests that either the mutations are not disease causing, or that the heterologous expression system is failing to capture the true effect of the mutation (Kim et al., 1997; Kopecka, Krijt, Rakova, & Kozich, 2011; Maclean et al., 2002) . the issue of neonatal lethality, our lab created a transgenic mouse in which the human CBS encoding cDNA was placed downstream of the mouse metallothionein (MT-I) promoter (Tg-hCBS) (Wang et al., 2004) . These mice were then crossed to Cbs +/− mice to generate heterozygous transgene positive animals (Tg-hCBS Cbs +/− ), which were then intercrossed on zinc water to generate Tg-hCBS Cbs −/− mice.
These animals are born in the expected Mendelian ratio and have near 100% survival through adulthood. Surprisingly, neonatal lethality was also rescued by transgenes expressing two different patient derived missense alleles, p.I278T and p.S466L, despite both enzymes having <5% of the enzyme activity of the wild-type enzyme (Gupta et al., 2013; Wang et al., 2005) . Interestingly, the p.S466L mutation shows high levels of enzyme activity in E. coli and S. cerevisiae, but is subject to degradation when expressed in mouse liver (Gupta et al., 2008; Janosik, Kery, Gaustadnes, Maclean, & Kraus, 2001 ).
p.R266K is a mutation that was initially identified in multiple patients from Norway. Untreated homozygous patients had very high tHcy levels, but all were highly responsive to treatment with pyridoxine (Kim et al., 1997) . The mutation is located near the heme-binding site and biophysical studies indicate that the mutation slightly alters heme binding to the enzyme (Melenovska et al., 2015; Smith et al., 2012) . However, in heterologous expression systems, the enzyme is extremely active and has very modest differences compared to the wild-type enzyme . Thus, it is not clear why this mutation causes severe homocystinuria.
Here, we have created a transgenic mouse (Tg-R266K Cbs −/− ) that is lacking endogenous mouse Cbs and expresses p.R266K encoding human CBS (hCBS) using a zinc-inducible promoter. Like untreated human homozygous patients, our mice have extremely elevated serum tHcy and lack significant levels of CBS activity in the liver. Treatment of our mice with a proteasome inhibitor, but not pyridoxine, restores liver CBS activity and lowers serum tHcy to near normal levels. Our studies indicate that in vivo p.R266K hCBS is unstable and degraded by the proteasome.
MATERIALS AND METHODS

DNA and constructs
All nucleotide numbering is based on the GenBank RefSeq NM_000071.1. The DNA mutation numbering system is based on the cDNA with +1 corresponding to the A or the ATG translation initiation codon in the reference sequence. Codon 1 is the initiator in the protein sequence. Site-directed mutagenesis was used to introduce a c.797 G>A (p.R266K) change into pLW2, which contains a hemagglutinin epitope tagged version of the human CBS cDNA (Wang et al., 2004) 
Mouse generation
Transgenic mice containing pLW3:R266K were created as previously described (Wang et al., 2004) . In brief, DNA was digested with SalI to release bacterial sequences, and the purified fragment was microinjected into the pronuclei of day 0.5 C57BL/6JxC3H/HeJ F2 embryos. Approximately 70 injected embryos were then transferred to pseudopregnant mice, which resulted in the birth of 21 pups. Tails from the resulting pups were then screened for the presence of the transgene by PCR as described (Wang et al., 2004) , and only one positive animal (female) was obtained. This DNA positive female was then backcrossed to a C57BL/6J male and six of eleven offspring were transgene positive, indicating germline inheritance.
To create Tg-R266K Cbs −/− mice, transgene positive offspring were bred to C57BL/6J Cbs − heterozygous animals (Watanabe et al., 1995) originally obtained from Jackson Laboratories (Bar Harbor, ME) to obtain Tg + Cbs −/+ animals. These animals were then backcrossed again to C57BL/6J Cbs − heterozygous animals to obtain Tg + Cbs −/− animals. Mice were on Zn water for these crosses (25 mM ZnSO 4 ).
Once it became clear that the vast majority of Tg-R266K Cbs −/− mice were not surviving into adulthood, Tg-R266K Cbs +/− mice were backcrossed with C3H/HeJ mice for at least three generations before again intercrossing.
Genotyping of offspring was generally done between 10 and 14 days of age as previously described (Wang et al., 2004) . Animals were fed standard rodent chow (Teklad 2018SX) containing 0.6% methionine by weight.
Pyridoxine and bortezomib studies in mice
A cohort of Tg-R266K Cbs −/− mice were studied under control (regular water), zinc water (25mM; 14 days), and zinc water supplemented with pyridoxine (0.4g/L; Sigma Aldrich P5669; 14 days) conditions. For most experiments only female mice were used as previous studies have shown that female mice more consistently induce Mt-I driven transgenes (Wang et al., 2004; Wang et al., 2005) . Mice ranged in age from 88-250 days of age. Blood was collected by retro-orbital bleed to measure serum tHcy and methionine.
Bortezomib (Velcade, Millennium Pharmaceuticals, Cambridge, MA, USA) was obtained from the pharmacy at Fox Chase Cancer Center. Adult female Tg-R266K Cbs −/− mice (n = 8) were subcutaneously implanted with Alzet microosmotic pumps (Model 2001; pumping rate 1 microliter/hr) containing bortezomib diluted in 0.9% NaCl to deliver a final dose of 0.49 mg/kg/day. Mice were on zinc water 11 days before the pump implant and through the duration of drug studies, and were also eye bled before the implant to extract serum. Mice were sacrificed after two days on pump to harvest liver and serum.
Metabolite measurements
Serum tHcy and methionine were measured using a Biochrom 30 amino acid analyzer as previously described (Wang et al., 2004) . The sum total of all forms of homocysteine including protein bound, free reduced and free oxidized, is referred to as tHcy. 
Western blotting and CBS enzyme activity
Liver homogenates were prepared as previously described (Shan, Dunbrack, Christopher, & Kruger, 2001; Wang et al., 2005) . For Western blotting, 30 g of total protein extract was electrophoresed on a 7% NuPAGE Tris-Acetate gel (Novex, Life Technologies) under denaturing conditions followed by transfer on to a PVDF membrane (Bio Rad) CBS was detected using a polyclonal rabbit anti-human primary antibody (1:10,000) and secondary anti-rabbit antibody (1:30,000) conjugated with horse radish peroxidase (GE Healthcare). Signal was visualized by SuperSignal West Pico Chemiluminescent kit (Thermo Scientific), and signal was measured by using Alpha Innotech image analyzer. Relative CBS protein levels ( Figure 1d ) were calculated by taking the absolute pixel count for CBS, dividing by the actin pixel count for the same sample, and multiplying by 10.
CBS activity was analyzed in the presence and absence of AdoMet (250 M) as previously described (Wang et al., 2004) . Reactions contained 30 g of dialyzed liver extracts, 5 mM L-serine, 10 mM DLhomocysteine and 50 M pyridoxal phosphate. One unit of activity is defined as nmoles of cystathionine formed per milligram of protein per hour.
Quantitative real time PCR
RNA was extracted from livers using TRIzol (Life Technologies) followed by cleanup using Qiagen RNeasy Mini kit. Gene expression analysis was done using Taq Man probes for human CBS (Hs00163925_m1, Applied Biosystems) and mouse -actin (Mm01205647_g1).
Quantification of signal was achieved using an Applied Biosystems 7900 HT detection system. Each sample was assayed in duplicate for both probes, and averages were used for statistical analysis.
Relative signal strength was calculated using the ΔΔC t method (Livak & Schmittgen, 2001 ).
Histology
Haematoxylin and eosin (H and E) staining was performed on livers fixed in 10% formalin as previously described (Wang et al., 2005) .
Statistics
All values cited in text and figures are arithmetic mean ± standard deviation. T-tests are all two-sided with a p<0.05 considered significant.
One-way ANOVA (analysis of variance) followed by a post-hoc Tukey's test was used in experiments that involved multiple comparisons.
RESULTS
Tg-R266K does not rescue neonatal lethality and mice have hyperhomocysteinemia
To understand the effect of the p.R266K mutation in vivo, we created a DNA construct that contains a hemagglutinin (HA)-tagged p.R266K
CBS encoding cDNA downstream of the mouse MT-I promoter, in a manner analogous to that used previously to express other human CBS alleles (Wang et al., 2004) . A single founder was obtained which was then backcrossed to C57BL/6J animals to confirm Mendelian transmission and transgene expression in response to zinc (Supp. Fig. S1 ). Fig. S2 ).
The few Tg-R266K Cbs −/− mice that survived into adulthood tended to be smaller than their Cbs +/− or Cbs +/+ littermates. In addition, as they aged, they showed the loss of hair of both the face and upper torso, similar to that observed in Tg-I278T Cbs −/− mice (Fig. 1A ). These adult survivors had significantly elevated serum tHcy and methionine and barely detectable levels of liver CBS activity. However, this resid- (Fig. 1D ). These findings show that there is less p.R266K protein relative to transcript compared to hCBS protein, suggesting that either protein stability or translational efficiency is impaired.
To circumvent the high degree of neonatal lethality, we crossed our mice with C3H/HeJ mice, as Cbs −/− neonatal lethality rates are reduced on this background (Akahoshi et al., 2008) . After three backcrosses, 31 out of 35 (89%) Tg-R266K Cbs −/− mice lived greater than six weeks of age. Zinc-treated adult Tg-R266K Cbs −/− mice on the C3H/HeJ background tended to have slightly lower serum tHcy and slightly more liver CBS activity than surviving Tg-R266K Cbs −/− mice on the C57BL6/J background (Fig. 2) . However, the amount of CBS activity in the C3H/HeJ livers was only about 2% of that found in hCBS expressing livers. Although activity was slightly higher in the C3H/HeJ samples compared to the C57BL/6J samples, the amount of CBS protein appeared to be comparable.
Pyridoxine supplementation does not restore function to p.R266K hCBS
Since p.R266K was associated with strong pyridoxine responsive behavior in human patients, we decided to investigate the effect of PLP on CBS activity in dialyzed liver extracts from mice expressing either hCBS or p.R266K in both C57BL/6J and C3H/HeJ backgrounds (Fig. 3A) . Addition of either 50 or 200 M PLP to the in vitro We also examined the effect of pyridoxine supplementation in vivo.
A cohort of C3H/HeJ mice were examined under three different conditions: (1) control, (2) zinc water supplemented, and (3) zinc water containing 0.04% pyridoxine. It should be noted that the amount of pyridoxine added was four times greater than used in our previous study on Tg-I278T Cbs −/− , which caused a 7-fold increase in serum PLP levels (Chen, Wang, Fazlieva, & Kruger, 2006) . Despite this fact, we observed no statistically significant differences in by any of the three treatments (Fig. 3B) . Thus, neither the in vitro or in vivo studies demonstrated that mouse-liver produced p.R266K was responsive to pyridoxine.
Bortezomib restoration of p.R266K function
Because p.R266K appeared to have reduced stability compared to hCBS, we examined if treatment with the proteasome inhibitor bortezomib could rescue CBS function. Zinc-treated Tg-R266K Cbs −/− mice (C3H/HeJ) were surgically implanted with an osmotic pump that delivered bortezomib at a dose of 0.49 mg/kg/day. After two days, the mice were euthanized, and blood and liver were collected for analysis. Bortezomib treated animals exhibited a dramatic lowering in both serum tHcy and a more modest lowering in Met in response to the treatment (Fig. 4A) . Serum tHcy levels went from 197 M before pump implantation to 6.1 M, which is only slightly higher than normal mouse tHcy levels. CBS protein in liver extracts from treated animals was much higher than in untreated animals and was similar to the F I G U R E 5 CBS activity and pyridoxine response in bortezomibtreated liver extracts. A: CBS enzyme activity in extracts from bortezomib-treated mice of the indicated genotype in the presence and absence of AdoMet. Error bar shows SD (n = 4 for each group). B: Ratio of CBS enzyme activity of indicated samples in the presence and absence of added PLP in reaction mixture amount observed in a zinc-induced Tg-hCBS Cbs −/− (C57BL/6J) mouse (Fig. 4B) . Activity studies showed that liver extracts containing bortezomib rescued p.R266K had similar levels of activity as hCBS protein derived from the livers of non-bortezomib treated Tg-hCBS Cbs −/− mice (Fig. 5A ). In addition, the bortezomib rescued p.R266K protein responded similarly to allosteric stimulation by AdoMet.
We also examined the sensitivity of the bortezomib rescued p.R266K to PLP in vitro. Our reasoning was that the protein instability of p.R266K might be something specific to mice and, if the protein was stabilized, we might now be able to see a differential response to PLP.
Therefore, we measured the ratio of enzyme activity in the presence and absence of PLP in the reaction mix. There was no difference in the sensitivity to PLP depletion in the reaction mixture (Fig. 5B) , suggesting that the bortezomib stabilized p.R266K was also not rescuable by PLP.
DISCUSSION
In this paper, we have analyzed the p.R266K mutation in the mouse model of CBS deficiency. This mutation is interesting because it has been found homozygous in multiple CBS deficient patients, but in vitro studies of the mutant enzyme indicate that it is nearly as active as wildtype CBS . In addition, patients homozygous of this allele strongly respond to pyridoxine, with their post-treatment tHcy levels reaching normal levels (Kim et al., 1997 Cbs −/− animals on a mostly C57BL/6J background were present in litters at 10-14 days, but 80% of the animals died by 30 days of age.
Our lab previously showed that not only could hCBS rescue this neonatal lethality, but so could two patient derived missense alleles (p.I278T and p.S466L) (Gupta et al., 2008; Wang et al., 2005) . Both of these alleles showed minimal levels of enzyme activity in liver extracts, similar to the activity found in p.R266K livers. With regards to steady-state protein levels, p.I278T animals tended to have more protein than p.R266K
animals, but in some p.S466L animals, we observed levels similar to the p.R266K mice (Gupta et al., 2013; Gupta et al., 2008) . A possible explanation for the difference in neonatal lethality is that neonatal death is not directly related to CBS's known enzymatic function, but may actually reflect an additional "moonlighting" function. Support for this idea comes from the observation that tHcy levels in surviving Tg − Cbs −/− adult mice are no different than those of Tg-I278T Cbs −/− mice (Wang et al., 2005) . In addition, we did not observe that tHcy levels of 18 day old Tg-R266K Cbs −/− mice were any higher than in 18 day old Tg-I278T Cbs −/− mice (unpublished data), suggesting that elevated tHcy is not directly related to the neonatal lethality. These findings are consistent with the idea that p.R266K affects an undefined moonlighting function, but p.I278T and p.S466L do not. Interestingly, our finding that out crossing onto the C3H/HeJ background can largely rescue the phenotype, reducing lethality from 80 to 10%, indicates that whatever the cause of the lethality is, it is largely strain specific.
Adult Tg-R266K Cbs −/− mice (on zinc) in both C57BL6/J and C3H/HeJ backgrounds have extremely elevated tHcy levels, which is similar to human p.R266K homozygotes (Kim et al., 1997) . On the surface, this finding seems at odds with a variety of studies on recombinant p.R266K, which shows the enzyme to be highly active (Chen et al., 2006; . In fact, when expressed in mammalian CHO-K1 cells, the protein was quite stable and formed tetramers at 77% of the level found in cells expressing wild-type human CBS, and had 50% of the enzyme activity (Melenovska et al., 2015) . However, Fig. 1D ). Thus, the difference in protein levels either reflects differences in protein synthesis (translational efficiency) or protein degradation. The finding that treatment with proteasome inhibitors resulted in a large increase in protein levels in Tg-R266K Cbs −/− mice supports the view that increased degradation is the most likely explanation.
These findings illustrate an important limitation of bacterial and yeastbased assays in assessing the functional relevance of specific mutations. More specifically, our studies show that the proteostasis environment (Balch, Morimoto, Dillin, & Kelly, 2008) can play a key role in determining the stability effects of a specific missense mutation, i.e., the intracellular environment of E. coli and S. cerevisiae allows p.R266K
to fold into an active functional form, while the environment in mouse liver does not.
In human patients, the p.R266K alteration is associated with an extremely robust response to pyridoxine. All five patients containing this allele (four homozgyotes and one presumed compound heterozygote) had post treatment tHcy in the normal range (Kim et al., 1997) . However, mouse liver produced p.R266K exhibited no significant response to either pyridoxine supplementation in vivo or PLP addition in vitro. These findings were identical to our studies of the p.I278T
allele, which are also associated with pyridoxine response in human patients. One possible explanation is that there are differences in the proteostasis environment between mouse and human liver, such that p.R266K has sufficient time to achieve a stable folded form in human, but does not in mouse. Therefore, we further speculated that if given time to fold properly, this form might then show increased sensitivity to PLP. However when we tried to mimic this, using proteasome inhibitors to stabilize p.R266K and then comparing in vitro response to PLP addition, we found that bortezomib stabilized p.R266K was no more sensitive to pyridoxine depletion than WT hCBS. The inability to mimic pyridoxine response in mice suggests there may be underlying differences between mouse and human liver physiology with regards to pyridoxine.
Perhaps the most interesting finding was that treatment with bortezomib could restore both serum tHcy and liver CBS activity to wildtype levels in Tg-R266K Cbs −/− mice. This result shows that other than it being unstable, p.R266K hCBS is essentially fully active, and in agreement with other heterologous expression studies. We have previously tested bortezomib with two other patient derived alleles (p.S466L and p.I278T) and found that they also were rescuable. All of these studies involved relatively short (two to five day) treatment durations using implantable osmotic pumps to give continuous dosing to the mice.
However, continuous dosing is too toxic to consider for the long term studies. Further studies will need to be done to determine if noncontinuous dosing over a longer period could give similar results. If so, then use of bortezomib on CBS deficient patients might be worth pursuing.
